Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyu Hatano

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Current Opinion in HIV and AIDS|March 5, 2013
Immune activation and HIV persistence: considerations for novel therapeutic interventionsHiroyu Hatano
Trends in Microbiology|December 10, 2014
Elite control of HIV: is this the right model for a functional cure?Leslie R Cockerham, Hiroyu Hatano
Journal of Virus Eradication|April 29, 2016
Clinical outcomes and antiretroviral therapy in 'elite' controllers: a review of the literatureTrevor A Crowell, Hiroyu Hatano
BMJ (Clinical Research Ed.)|June 2, 2007
Drug resistant HIVHiroyu Hatano, Steven G Deeks
Current HIV/AIDS Reports|January 20, 2016
Post-Treatment Controllers: Role in HIV "Cure" ResearchLeslie R Cockerham, Hiroyu Hatano, Steven G Deeks
The Journal of Infectious Diseases|January 15, 2014
Reply to Karch et alHiroyu Hatano, Peter Bacchetti, Priscilla Y Hsue, et al.
Journal of Virology|July 1, 2006
Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1Zixin Hu, Françoise Giguel, Hiroyu Hatano, et al.
The Journal of Infectious Diseases|February 6, 2018
Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?Peter D Burbelo, Richard W Price, Lars Hagberg, et al.
Antimicrobial Agents and Chemotherapy|August 15, 2012
Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremiaJonathan Z Li, Sebastien Gallien, Tri D Do, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 20, 2006
Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimenHiroyu Hatano, Peter Hunt, Jodi Weidler, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Current Opinion in HIV and AIDS|March 5, 2013
Immune activation and HIV persistence: considerations for novel therapeutic interventionsHiroyu Hatano
Trends in Microbiology|December 10, 2014
Elite control of HIV: is this the right model for a functional cure?Leslie R Cockerham, Hiroyu Hatano
Journal of Virus Eradication|April 29, 2016
Clinical outcomes and antiretroviral therapy in 'elite' controllers: a review of the literatureTrevor A Crowell, Hiroyu Hatano
BMJ (Clinical Research Ed.)|June 2, 2007
Drug resistant HIVHiroyu Hatano, Steven G Deeks
Current HIV/AIDS Reports|January 20, 2016
Post-Treatment Controllers: Role in HIV "Cure" ResearchLeslie R Cockerham, Hiroyu Hatano, Steven G Deeks
The Journal of Infectious Diseases|January 15, 2014
Reply to Karch et alHiroyu Hatano, Peter Bacchetti, Priscilla Y Hsue, et al.
Journal of Virology|July 1, 2006
Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1Zixin Hu, Françoise Giguel, Hiroyu Hatano, et al.
The Journal of Infectious Diseases|February 6, 2018
Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?Peter D Burbelo, Richard W Price, Lars Hagberg, et al.
Antimicrobial Agents and Chemotherapy|August 15, 2012
Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremiaJonathan Z Li, Sebastien Gallien, Tri D Do, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 20, 2006
Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimenHiroyu Hatano, Peter Hunt, Jodi Weidler, et al.
Pageof 5